Loading company…
Madison Vaccines Incorporated develops DNA vaccine immunotherapies, mainly for prostate cancer, from its base in Madison, US.
Madison Vaccines Incorporated develops DNA vaccine therapies that aim to activate the immune system against cancer, with a focus on non-metastatic prostate cancer. Founded by Douglas McNeel and headquartered in Madison, US, the company raised USD 2.000 mn in a Series A round in March 2015 from Venture Management LLC, WARF Ventures and Venture Investors. That brings its total raised to USD 2.000 mn at a current valuation of USD 15.024 mn, and the funding is planned for an expanded Phase 2 trial of its DNA vaccine MVI-816.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in